Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet
Our results suggest that enavogliflozin is effective in a mouse model of MASH by attenuating hepatic steatosis, suppressing inflammation, and improving liver fibrosis.
Authors
- Jeana Hong (ORCID: https://orcid.org/0000-0003-0332-7466)
- Giang Nguyen (ORCID: https://orcid.org/0000-0001-9269-262X)
- Dae Hee Choi (ORCID: https://orcid.org/0000-0002-8956-7518)
- Seon Mee Kang (ORCID: https://orcid.org/0000-0002-4056-7525)
- Eun-Hee Cho (ORCID: https://orcid.org/0000-0002-1349-8894)
- So Young Park (ORCID: https://orcid.org/0000-0003-1518-2516)
- Tin Pou Lai
- Phuc Nguyen Huu Pham
Institutions
- Kangwon National University (KR)
Publication Details
- Journal
- Diabetes & Metabolism Journal
- Published
- 2025-06-16
- DOI
- https://doi.org/10.4093/dmj.2024.0259
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Daewoong Pharmaceutical Company